Top Page
Lumos Diagnostics Holdings Ltd.
(Sydney:LDX)
Lumos Diagnostics Holdings Ltd. (LDX) vs. iShares MSCI Australia ETF (EWA)
Lumos Diagnostics Holdings Ltd. Business Overview & Revenue Model
Lumos Diagnostics Holdings Ltd. Earnings Call Summary
Lumos Diagnostics Holdings Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.40M | 12.50M | 11.13M | 10.54M | 11.63M | 18.85M |
| Gross Profit | 7.68M | 7.91M | 7.10M | 5.32M | 4.46M | 8.60M |
| EBITDA | -6.08M | -4.63M | -5.44M | -4.93M | -25.67M | -10.69M |
| Net Income | -7.18M | -7.18M | -8.59M | -8.97M | -45.72M | -15.03M |
Balance Sheet | ||||||
| Total Assets | 20.81M | 20.81M | 26.84M | 25.42M | 36.94M | 97.99M |
| Cash, Cash Equivalents and Short-Term Investments | 1.96M | 1.96M | 6.48M | 3.02M | 7.98M | 44.89M |
| Total Debt | 6.99M | 6.99M | 8.06M | 9.79M | 7.19M | 7.96M |
| Total Liabilities | 14.65M | 14.65M | 19.73M | 15.92M | 19.05M | 39.71M |
| Stockholders Equity | 6.16M | 6.16M | 7.11M | 9.50M | 17.89M | 58.28M |
Cash Flow | ||||||
| Free Cash Flow | -9.39M | -9.39M | 848.00K | -9.79M | -22.39M | -16.77M |
| Operating Cash Flow | -9.33M | -9.33M | 946.00K | -9.64M | -18.04M | -10.89M |
| Investing Cash Flow | -53.00K | -53.00K | -98.00K | 4.31M | -4.36M | -8.33M |
| Financing Cash Flow | 5.28M | 5.28M | 2.63M | 652.00K | -10.92M | 63.27M |
Lumos Diagnostics Holdings Ltd. Technical Analysis
Lumos Diagnostics Holdings Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$185.00M | -15.53 | -111.23% | ― | 12.96% | 40.81% | |
48 Neutral | AU$36.07M | -4.95 | -97.79% | ― | ― | 23.85% | |
47 Neutral | AU$28.65M | -6.90 | -501.54% | ― | ― | 56.42% | |
41 Neutral | AU$45.06M | -2.16 | -40.54% | ― | 29.60% | 33.00% | |
41 Neutral | AU$54.51M | -2.65 | -36.16% | ― | 62.81% | 16.37% | |
38 Underperform | AU$46.46M | -5.46 | -37.78% | ― | 2.33% | 12.50% |
Lumos Diagnostics Holdings Ltd. Corporate Events
Lumos Diagnostics Holdings Ltd has issued 35,341 fully paid ordinary shares following the exercise of 42,000 unquoted options by its employees. This issuance was conducted without disclosure under the Corporations Act, and the company confirms its compliance with relevant statutory provisions, indicating a transparent and regulated approach to its operational activities.
Lumos Diagnostics Holdings Ltd. has announced the quotation of 35,341 fully paid ordinary securities on the ASX, following the exercise of options or conversion of other convertible securities. This move is part of the company’s ongoing efforts to enhance its financial flexibility and strengthen its market position, potentially impacting its operational capabilities and offering growth opportunities for stakeholders.
Lumos Diagnostics has achieved full U.S. Medicare reimbursement recognition for its FebriDx® test, securing approval from all seven Medicare Administrative Contractors (MACs), including the final approval from National Government Services. This development ensures FebriDx is positioned for broad adoption across the U.S. healthcare system, facilitating access through Medicare Advantage, Medicaid, and private payors. The company will now focus on assisting MACs in developing written policies to streamline reimbursement claims, enhancing clarity and predictability for stakeholders.
Lumos Diagnostics Holdings Ltd. has announced the issuance of 6,007,000 performance rights as part of an employee incentive scheme. This move is aimed at enhancing employee engagement and aligning their interests with the company’s growth objectives, potentially impacting the company’s operational dynamics and stakeholder interests positively.
Lumos Diagnostics Holdings Ltd. has announced the quotation of 1,323,875 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of October 31, 2025. This move is part of the company’s strategy to enhance its financial flexibility and potentially expand its market presence, impacting its operations and positioning within the healthcare diagnostics industry.
Lumos Diagnostics Holdings Ltd has announced a change in the director’s interest, with Doug Ward acquiring 22,000,000 performance rights. This change, approved by shareholders at the company’s 2025 Annual General Meeting, reflects a strategic move to align the interests of the director with the company’s growth objectives, potentially impacting the company’s operations and stakeholder interests.
Lumos Diagnostics Holdings Ltd. announced the issuance of 22 million unquoted performance rights as part of an employee incentive scheme. This move is likely to enhance employee engagement and align their interests with the company’s growth objectives, potentially impacting its operational efficiency and market positioning.
Lumos Diagnostics has announced the adoption of a revised Constitution, as approved by shareholders at their 2025 Annual General Meeting. This update is part of the company’s ongoing efforts to align its governance framework with current operational and strategic needs, potentially impacting its operational efficiency and stakeholder engagement.
Lumos Diagnostics Holdings Ltd. announced the results of its 2025 Annual General Meeting, where all proposed resolutions were carried. Key resolutions included the adoption of the remuneration report, re-election of a director, approval of performance rights, and ratification of share issues. These outcomes reflect strong shareholder support and are expected to positively impact the company’s governance and strategic initiatives.
Lumos Diagnostics Holdings Ltd. recently held its Annual General Meeting, where the CEO presented key updates about the company’s operations and strategic direction. The presentation emphasized the company’s commitment to advancing its diagnostic solutions and highlighted the challenges and opportunities in the market. While the document provided valuable insights into Lumos’ market positioning and future plans, it also contained disclaimers about forward-looking statements, advising stakeholders to consider the inherent risks and uncertainties.
Lumos Diagnostics has made significant strides in FY25, transitioning from an early-stage business to an emerging global diagnostics company. The company has expanded its distribution partnerships, notably with Henry Schein and PHASE Scientific, and has secured reimbursement for FebriDx on the U.S. Medicare fee schedule. A successful CLIA waiver trial for FebriDx has been completed, with the application submitted to the FDA, potentially expanding the U.S. market significantly. A new distribution agreement with PHASE Scientific could be worth up to US$317 million, marking a major milestone for Lumos. The company remains well-funded, with a focus on disciplined execution and expanding its product’s clinical use, supported by BARDA.
Lumos Diagnostics reported a steady revenue of US$3.4 million for the first quarter of FY26, with a notable 300% increase in product revenue driven by the adoption of FebriDx® in the U.S. The company secured a significant distribution agreement with PHASE Scientific and is awaiting feedback on a CLIA waiver submission for FebriDx. Lumos also continues its development projects, including an expanded agreement with Hologic for a next-generation diagnostic product, and has secured a loan facility to support its working capital needs.
Lumos Diagnostics Holdings Ltd has initiated a pediatric study for its FebriDx® device in the United States, targeting children aged 2 to 12 years. This study, supported by BARDA with significant funding, aims to expand the device’s usage to differentiate bacterial from non-bacterial acute respiratory infections in younger children, potentially increasing Lumos’ market reach significantly if successful.
Lumos Diagnostics has entered into an agreement with WellStreet Urgent Care to advance the use of its FebriDx® testing through a joint venture with Piedmont Healthcare in Atlanta, Georgia. The program, set to begin in October 2025, will involve WellStreet procuring and submitting reimbursement claims for each test, with PHASE Scientific leading distribution and Pro-spectus managing billing data. The collaboration aims to provide operational insights and establish future coverage policies with national insurance organizations. If a CLIA waiver is granted, the initiative could expand to approximately 140 WellStreet locations across the US, enhancing Lumos’ market presence and operational scalability.
Lumos Diagnostics has issued an addendum to its Notice of Annual General Meeting, addressing shareholder queries regarding the timing and vesting conditions of performance rights for its CEO, Douglas Ward. The addendum does not alter the validity of previously submitted proxy votes and provides shareholders with additional details to consider before the meeting on October 24, 2025.
Lumos Diagnostics has released real-world data on its FebriDx® test, presented at the Primary Care Respiratory Society Annual Conference. The data highlights the test’s effectiveness in reducing antibiotic prescriptions, improving patient experiences, and generating significant cost savings for healthcare systems by distinguishing between viral and bacterial infections. This development underscores the potential of FebriDx® to enhance clinical decision-making, address antimicrobial resistance, and optimize healthcare resource utilization.
Lumos Diagnostics, a leader in rapid point-of-care diagnostic technologies, announced its participation in the ASX SMIDcaps 2025 Conference, where its CFO, Barrie Lambert, will deliver a presentation. This engagement highlights Lumos’ active role in the diagnostics industry and its commitment to advancing healthcare solutions, potentially enhancing its market presence and stakeholder relations.
Lumos Diagnostics Holdings Ltd. has announced its Annual General Meeting (AGM) will be held virtually on October 24, 2025, via a Zoom webinar. Shareholders are encouraged to register in advance and submit their proxy forms early. The virtual format allows shareholders to participate in discussions and vote on resolutions, ensuring continued engagement despite potential disruptions.
Lumos Diagnostics Holdings Ltd has issued a total of 10,193,868 fully paid ordinary shares following the exercise of options by SBC Global Investment Fund and an employee. This issuance, conducted without disclosure under specific sections of the Corporations Act, signifies a strategic move to enhance the company’s capital structure, potentially impacting its market positioning and stakeholder interests.
Lumos Diagnostics Holdings Ltd. announced the quotation of 10,193,868 fully paid ordinary securities on the ASX, effective from September 11, 2025. This move is part of their strategic efforts to enhance liquidity and strengthen their financial position, potentially impacting their market presence and stakeholder interests positively.
Lumos Diagnostics Holdings Ltd. has announced a new application for the quotation of 15,000,000 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of a previously announced transaction, indicating strategic financial maneuvers that could enhance the company’s market presence and liquidity.
Lumos Diagnostics has signed a second distribution agreement for its FebriDx® test in Australia and New Zealand with Amtech, part of YesGroup. This partnership, alongside an existing agreement with Henry Schein, aims to expand the accessibility of FebriDx®, a rapid test that differentiates between bacterial and viral infections, thereby supporting informed clinical decisions and reducing unnecessary antibiotic use.
Lumos Diagnostics has secured a A$5.0 million loan facility with major shareholders Tenmile Ventures and Ryder Capital, providing financial flexibility as it seeks a CLIA waiver from the U.S. FDA for its FebriDx® test. This agreement replaces a previous convertible note arrangement and aims to support the company’s strategic goals while minimizing equity dilution, highlighting the ongoing commitment of its shareholders.